Top

Published in:

01-09-2015 | Original Article

Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer’s disease (AD)

Authors: Melissa J. Alldred, Sang Han Lee, Eva Petkova, Stephen D. Ginsberg

Published in: Brain Structure and Function | Issue 5/2015

Abstract

Down syndrome (DS) is caused by the triplication of human chromosome 21 (HSA21) and is the most common genetic cause of intellectual disability, with individuals having deficits in cognitive function including hippocampal learning and memory and neurodegeneration of cholinergic basal forebrain neurons, a pathological hallmark of Alzheimer’s disease (AD). To date, the molecular underpinnings driving this pathology have not been elucidated. The Ts65Dn mouse is a segmental trisomy model of DS and like DS/AD pathology, displays age-related cognitive dysfunction and basal forebrain cholinergic neuron (BFCN) degeneration. To determine molecular and cellular changes important for elucidating mechanisms of neurodegeneration in DS/AD pathology, expression profiling studies were performed. Molecular fingerprinting of homogeneous populations of Cornu Ammonis 1 (CA1) pyramidal neurons was performed via laser capture microdissection followed by Terminal Continuation RNA amplification combined with custom-designed microarray analysis and subsequent validation of individual transcripts by qPCR and protein analysis via immunoblotting. Significant alterations were observed within CA1 pyramidal neurons of aged Ts65Dn mice compared to normal disomic (2N) littermates, notably in excitatory and inhibitory neurotransmission receptor families and neurotrophins, including brain-derived neurotrophic factor as well as several cognate neurotrophin receptors. Examining gene and protein expression levels after the onset of BFCN degeneration elucidated transcriptional and translational changes in neurons within a vulnerable circuit that may cause the AD-like pathology seen in DS as these individuals age, and provide rational targets for therapeutic interventions.

Available only for authorised users

Akeson E, Lambert J (2001) Ts65Dn–localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet Cell Genet 276:270–276CrossRef

Alldred MJ, Che S, Ginsberg SD (2008) Terminal continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. Int J Mol Sci 9:2091–2104PubMedCentralCrossRefPubMed

Alldred MJ, Che S, Ginsberg SD (2009) Terminal continuation (TC) RNA amplification without second strand synthesis. J Neurosci Methods 177:381–385PubMedCentralCrossRefPubMed

Alldred MJ, Duff KE, Ginsberg SD (2012) Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis 45:751–762PubMedCentralCrossRefPubMed

Applied Biosystems (2008) Guide to performing relative quantitation of gene expression using real-time quantitative PCR. Gene Expr 2009:1–60

Belichenko PV, Masliah E, Kleschevnikov AM et al (2004) Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 480:281–298CrossRefPubMed

Belichenko NP, Belichenko PV, Kleschevnikov AM et al (2009) The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 29:5938–5948PubMedCentralCrossRefPubMed

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300

Boada R, Hutaff-Lee C, Schrader A et al (2012) Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2:e141PubMedCentralCrossRefPubMed

Carter TL, Rissman RA, Mishizen-Eberz AJ et al (2004) Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer’s disease patients according to Braak stage. Exp Neurol 187:299–309CrossRefPubMed

Cataldo AM, Peterhoff CM, Troncoso JC et al (2000) Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer’s disease and Down syndrome. Am J Pathol 157:277–286PubMedCentralCrossRefPubMed

Cataldo AM, Petanceska S, Peterhoff CM et al (2003) App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of Down syndrome. J Neurosci 23:6788–6792PubMed

Chao MV (2003) Retrograde transport redux. Neuron 39:1–2CrossRefPubMed

Chapman R, Hesketh L (2000) Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 95:84–95CrossRef

Che S, Ginsberg SD (2004) Amplification of RNA transcripts using terminal continuation. Lab Invest 84:131–137CrossRefPubMed

Chen Z, Simmons MS, Perry RT et al (2008) Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147:363–369CrossRefPubMed

Chen Y, Dyakin VV, Branch CA et al (2009) In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol Aging 30:1453–1465PubMedCentralCrossRefPubMed

Chong S-A, Benilova I, Shaban H et al (2011) Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer’s disease: a multi-electrode array study. Neurobiol Dis 44:284–291CrossRefPubMed

Cooper JD, Salehi A, Delcroix JD et al (2001) Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 98:10439–10444PubMedCentralCrossRefPubMed

Costa ACS, Scott-McKean JJ, Stasko MR (2008) Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33:1624–1632CrossRefPubMed

Counts SE, Che S, Ginsberg SD, Mufson EJ (2011) Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer’s disease. J Chem Neuroanat 42:111–117PubMedCentralCrossRefPubMed

Counts SE, Alldred MJ, Che S et al (2014) Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology 79:172–179PubMedCentralCrossRefPubMed

Dang V, Medina B, Das D et al (2014) Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry 75:179–188CrossRefPubMed

Danysz W, Parsons CG (2012) Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine—searching for the connections. Br J Pharmacol 167:324–352PubMedCentralCrossRefPubMed

Das I, Reeves RH (2011) The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech 4:596–606PubMedCentralCrossRefPubMed

Davisson M, Schmidt C, Reeves RH et al (1993) Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res 384:117–133PubMed

Efron B (2007) Correlation and large-scale simultaneous significance testing. J Am Stat Assoc 102:93–103CrossRef

Esbensen AJ (2010) Health conditions associated with aging and end of life of adults with Down syndrome. Int Rev Res Ment Retard 39:107–126PubMedCentralCrossRefPubMed

Escorihuela RM, Fernández-Teruel A, Vallina IF et al (1995) A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 199:143–146CrossRefPubMed

Gardiner K, Fortna A, Bechtel L, Davisson MT (2003) Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318:137–147CrossRefPubMed

Ginsberg SD (2005a) Glutamatergic neurotransmission expression profiling in the mouse hippocampus after perforant-path transection. Am J Geriatr Pyschiatry 13:1052–1061CrossRef

Ginsberg SD (2005b) RNA amplification strategies for small sample populations. Methods 37:229–237CrossRefPubMed

Ginsberg SD (2007) Expression profile analysis of brain aging. In: Riddle DR (ed) Brain aging: models, methods and mechanisms. CRC Press, New York, pp 159–185CrossRef

Ginsberg SD (2008) Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol 439:147–158PubMedCentralCrossRefPubMed

Ginsberg SD (2009) Microarray use for the analysis of the CNS. In: Squire LR (ed) Encyclopedia of neuroscience, vol 5. Academic Press, Oxford, pp 835–841CrossRef

Ginsberg SD, Mirnics K (2006) Functional genomic methodologies. Prog Brain Res 158:15–40CrossRefPubMed

Ginsberg SD, Che S, Wuu J et al (2006) Down regulation of trk but not p75^NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem 97:475–487CrossRefPubMed

Ginsberg SD, Alldred MJ, Counts SE et al (2010a) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol Psychiatry 68:885–893PubMedCentralCrossRefPubMed

Ginsberg SD, Mufson EJ, Counts SE et al (2010b) Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 22:631–639PubMedCentralPubMed

Ginsberg SD, Alldred MJ, Che S (2012) Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer’s disease. Neurobiol Dis 45:99–107PubMedCentralCrossRefPubMed

Granholm AC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down’s syndrome. Exp Neurol 161:647–663CrossRefPubMed

Granholm A-C, Sanders L, Seo H et al (2003) Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome. Hippocampus 13:905–914CrossRefPubMed

Gygi SP, Rochon Y, Franza BR, Aebersold R (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19:1720–1730PubMedCentralPubMed

Hanney M, Prasher V, Williams N et al (2012) Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379:528–536CrossRefPubMed

Holtzman DM, Santucci D, Kilbridge J et al (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93:13333–13338PubMedCentralCrossRefPubMed

Howe CL, Mobley WC (2004) Signaling endosome hypothesis: a cellular mechanism for long distance communication. J Neurobiol 58:207–216CrossRefPubMed

Huang YZ, McNamara JO (2012) Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB. J Neurosci 32:15521–15532PubMedCentralCrossRefPubMed

Hunter CL, Isacson O, Nelson M et al (2003) Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down’s syndrome. Neurosci Res 45:437–445CrossRefPubMed

Hyde LA, Crnic LS (2001) Age-related deficits in context discrimination learning in Ts65Dn mice that model Down syndrome and Alzheimer’s disease. Behav Neurosci 115:1239–1246CrossRefPubMed

Ikonomovic MD, Sheffield R, Armstrong DM (1995) AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer’s disease. Hippocampus 5:469–486CrossRefPubMed

Ikonomovic MD, Mizukami K, Davies P et al (1997) The loss of GluR2 (3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brain. J Neuropathol Exp Neurol 56:1018–1027CrossRefPubMed

Insausti AM, Megías M, Crespo D et al (1998) Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci Lett 253:175–178CrossRefPubMed

Jacobs PA, Hassold TJ (1995) The origin of numerical chromosome abnormalities. Adv Genet 33:101–133CrossRefPubMed

Jiang Y, Mullaney KA, Peterhoff CM et al (2010) Alzheimer’s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 107:1630–1635PubMedCentralCrossRefPubMed

Kaur G, Sharma A, Xu W et al (2014) Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down’s syndrome. J Neurosci 34:5099–5106PubMedCentralCrossRefPubMed

Kelley C, Powers B, Velazquez R (2014a) Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease. Brain Pathol 24:33–44PubMedCentralCrossRefPubMed

Kelley CM, Powers BE, Velazquez R et al (2014b) Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice. J Comp Neurol 522:1390–1410PubMedCentralCrossRefPubMed

Kervern M, Angeli A, Nicole O et al (2012) Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimers Dis 32:183–196PubMed

Koch G, Di Lorenzo F, Bonnì S et al (2012) Impaired LTP- but not LTD-like cortical plasticity in Alzheimer’s disease patients. J Alzheimers Dis 31:593–599PubMed

Köhler C, Chan-Palay V, Wu JY (1984) Septal neurons containing glutamic acid decarboxylase immunoreactivity project to the hippocampal region in the rat brain. Anat Embryol (Berl) 169:41–44CrossRef

Kurt MA, Davies DC, Kidd M et al (2000) Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res 858:191–197CrossRefPubMed

Leverenz JB, Raskind MA (1998) Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296–304CrossRefPubMed

Lockrow J, Prakasam A et al (2009) Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 216:278–289PubMedCentralCrossRefPubMed

Lockrow J, Boger H, Bimonte-Nelson H, Granholm A-C (2011a) Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 221:610–622PubMedCentralCrossRefPubMed

Lockrow J, Boger H, Gerhardt G et al (2011b) A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. J Alzheimers Dis 23:471–489PubMedCentralPubMed

Lorenzi HA, Reeves RH (2006) Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 1104:153–159CrossRefPubMed

Maeder ML, Linder SJ, Cascio VM et al (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977–979PubMedCentralCrossRefPubMed

Mann DM, Yates PO, Marcyniuk B, Ravindra CR (1986) The topography of plaques and tangles in Down’s syndrome patients of different ages. Neuropathol Appl Neurobiol 12:447–457CrossRefPubMed

McCulloch CE, Searle SR, Neuhaus JM (2008) Generalized, linear, and mixed models, 2nd edn. Wiley, New York

Middei S, Roberto A, Berretta N et al (2010) Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer’s disease. Learn Mem 17:236–240CrossRefPubMed

Moon J, Chen M, Gandhy SU et al (2010) Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav Neurosci 124:346–361PubMedCentralCrossRefPubMed

Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4:340–350CrossRefPubMed

Nakamura T, Lipton SA (2010) Preventing Ca2⁺ -mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium 47:190–197PubMedCentralCrossRefPubMed

Nixon RA, Cataldo AM (2006) Lysosomal system pathways: genes to neurodegeneration in Alzheimer’s disease. J Alzheimers Dis 9:277–289PubMed

Parker SE, Mai CT, Canfield MA et al (2010) Updated national birth prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res A Clin Mol Teratol 88:1008–1016CrossRefPubMed

Peterson GM, Williams LR, Varon S, Gage FH (1987) Loss of GABAergic neurons in medial septum after fimbria-fornix transection. Neurosci Lett 76:140–144CrossRefPubMed

Peterson GM, Lanford GW, Powell EW (1990) Fate of septohippocampal neurons following fimbria-fornix transection: a time course analysis. Brain Res Bull 25:129–137CrossRefPubMed

Pollonini G, Gao V, Rabe A, Palminiello S (2008) Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn. Neuroscience 156:99–106PubMedCentralCrossRefPubMed

Proctor DT, Coulson EJ, Dodd PR (2010) Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21:795–811PubMed

Rajagopal R, Chen Z-Y, Lee FS, Chao MV (2004) Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J Neurosci 24:6650–6658CrossRefPubMed

Rammes G, Hasenjäger A, Sroka-Saidi K et al (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60:982–990CrossRefPubMed

Reeves RH, Irving NG, Moran TH et al (1995) A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11:177–184CrossRefPubMed

Reisberg B, Doody R, Stöffler A (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341CrossRefPubMed

Reisberg B, Doody R, Stoffler A (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49–54CrossRefPubMed

Rueda N, Llorens-Martín M, Flórez J et al (2010) Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 21:277–290PubMed

Rueda N, Flórez J, Martínez-Cué C (2012) Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast 2012:584071PubMedCentralPubMed

Salehi A, Delcroix J-D, Belichenko PV et al (2006) Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29–42CrossRefPubMed

Saran NG, Pletcher MT, Natale JE et al (2003) Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet 12:2013–2019CrossRefPubMed

Shaulsky G, Loomis WF (2002) Gene expression patterns in Dictyostelium using microarrays. Protist 153:93–98CrossRefPubMed

Skaper SD (2008) The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 7:46–62CrossRefPubMed

Stempler S, Ruppin E (2012) Analyzing gene expression from whole tissue vs. different cell types reveals the central role of neurons in predicting severity of Alzheimer’s disease. PLoS One 7:e45879PubMedCentralCrossRefPubMed

Sturgeon X, Gardiner KJ (2011) Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome 22:261–271CrossRefPubMed

Talantova M, Sanz-Blasco S, Zhang X et al (2013) Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA 110:E2518–E2527PubMedCentralCrossRefPubMed

Tuszynski M (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1:51–57CrossRefPubMed

Tuszynski MH (2007) Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 21:179–189CrossRefPubMed

Velazquez R, Ash JA, Powers BE et al (2013) Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 58:92–101PubMedCentralCrossRefPubMed

Wang T, Huang Q, Reiman EM et al (2013) Effect of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia. J Clin Pyschopharmacol 33:636–642CrossRef

Williams R, Chung JY, Ylaya K et al (2010) Characterizations and validations of novel antibodies toward translational research. Proteomics Clin Appl 4:618–625CrossRefPubMed

Wisniewski K, Wisniewski H, Wen G (1985) Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 17:278–282CrossRefPubMed

Title: Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer’s disease (AD)
Authors: Melissa J. Alldred
Sang Han Lee
Eva Petkova
Stephen D. Ginsberg
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Brain Structure and Function / Issue 5/2015
Print ISSN: 1863-2653
Electronic ISSN: 1863-2661
DOI: https://doi.org/10.1007/s00429-014-0839-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer’s disease (AD)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain

Selective axonal and glial distribution of monoacylglycerol lipase immunoreactivity in the superficial spinal dorsal horn of rodents

A new automated 3D detection of synaptic contacts reveals the formation of cortico-striatal synapses upon cocaine treatment in vivo

Connectivity-based parcellation of the human frontal polar cortex

Global versus tract-specific components of cerebral white matter integrity: relation to adult age and perceptual-motor speed

Genetic ablation of VIAAT in glycinergic neurons causes a severe respiratory phenotype and perinatal death